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S U M M A R Y
Background: Because treatment outcomes of invasive aspergillosis (IA) remain suboptimal, clinicians
have resorted to the use of combination antifungal therapy. We therefore sought to systematically
review the evidence that addresses the role of combination antifungal therapy in the treatment of
invasive aspergillosis.
Methods: We retrieved the literature from MEDLINE, EMBASE, Web of Science, Cochrane Controlled
Trials Register, and Scopus from inception up to March 2011 for cohort and randomized controlled trial
(RCT) studies that assessed the efﬁcacy of combination antifungal therapy for IA and reported on clinical
outcomes.
Results: Eight studies (one RCT and seven cohort studies) that enrolled a total of 1071 patients met our
inclusion criteria. Six cohort studies examined the role of combination therapy for the primary treatment
of IA and two for salvage therapy. Various antifungal combinations were used, mainly azoles with either
an echinocandin or a polyene. Of the seven cohort studies, four reported adjusted effect estimates, one of
which showed a better outcome with combination antifungal therapy and one a trend towards a better
outcome, while the remaining two revealed that there was no added advantage of combination
antifungal therapy over monotherapy or a better response with monotherapy, respectively. The
randomized controlled trial revealed that the use of combination therapy was associated with a better
outcome.
Conclusion: Cumulative evidence supporting the use of combination antifungal therapy in IA is
conﬂicting and of moderate strength. Well-designed RCTs are required to adequately address the issue of
the usefulness of this approach.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Aspergillus species have emerged as important causes of life-
threatening infections, especially in immunocompromised
patients.1–3 The causative agents of invasive disease, A. fumigatus,
A. ﬂavus, A. terreus, and A. niger, cause a spectrum of infections
ranging from chronic necrotizing pneumonia to invasive pulmo-
nary aspergillosis (IPA) and other syndromes of tissue invasion.
The rising incidence of invasive aspergillosis (IA) has led to
signiﬁcant compromise in treatment outcomes, especially in
patients with hematologic malignancies and in hematopoietic
stem cell transplant recipients.4–8 Recent data from Upton et al.9
showed that the probability of survival at 90 days in patients with* Corresponding author. Tel.: +966 1 2889999 ext. 1299.
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doi:10.1016/j.ijid.2011.10.004IA diagnosed between 2002 and 2004 was higher compared with
those diagnosed between 1990 and 2001; 44% vs. 22%, respectively
(p < 0.0001). As the most common mould infection, IA has been the
‘ground zero’ of antifungal combination contention.
Amphotericin B deoxycholate (D-AMB) was the standard
therapy for IA for decades, though with suboptimal responses
and attendant side effects, especially in severely immunosup-
pressed patients.10–13 Few randomized controlled trials (RCTs)
exist on the treatment of IA, the largest of which demonstrated
that voriconazole was superior to D-AMB as primary treatment for
IA.14 This has led to the recommendation of voriconazole as ﬁrst-
line therapy for IA by the Infectious Diseases Society of America
(IDSA) (class A–level I evidence).15 In patients who fail initial
therapy, or who are intolerant of the initial regimen, second-line
drugs are often used to replace the failing or intolerant agent.
Administering both drugs simultaneously has not been well
supported16 and there are limited clinical data to supportses. Published by Elsevier Ltd. All rights reserved.
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primary treatment of IA.17
Combinations of azoles and echinocandins that target different
cellular sites have been used in in vitro studies, animal models, case
reports, and some studies in IA.18–23 There is signiﬁcant interest in
combination antifungal therapy pairing an echinocandin with either
an azole or amphotericin B formulation for the treatment of IA.
Antifungal agents with distinct mechanisms of action offer the
possibility of synergistic activity against invasive moulds when used
in combination.21,24–26 The possibility of antagonism is raised when
some of these drugs are given in combination, particularly
sequentially, with drugs blocking ergosterol synthesis given before
the polyenes.27–32 The most common reason for using or investi-
gating combinations of antifungal agents is the hope of achieving
synergy; however, detrimental effects, including attenuation of
activity, increased resistance or toxicity, increased cost, and drug
interactions, are hazards of combination therapy and must be
carefully considered, along with the difﬁculty of interpreting much
of the in vitro, animal, and clinical data in this arena. In the absence of
a well-controlled, prospective clinical trial, the combination of
antifungal drugs for primary therapy of IA is not routinely
recommended by IDSA (class B–level II evidence), but may be
considered in salvage situations.15 The addition of a second
antifungal agent to a ﬁrst one that is failing or toxic is usually
practiced out of understandable desperation. Nevertheless, limited
in vitro, in vivo, and non-randomized clinical trial data suggest the
beneﬁt of some forms of combination therapy against IA.17–23,33
Given the dismal prognosis of patients with IA, various
combinations of antifungal agents have been used to treat this
ailment. However, the efﬁcacy of this approach has not been
indisputably documented. High cost, toxicity, and insufﬁcient
supporting evidence pose limitations to this approach. We
therefore aimed to systematically review the available literature
to critically evaluate and summarize the evidence for this approach
in the treatment of IA.
2. Methods
2.1. Review question and study protocol
We aimed to systematically review the effectiveness of
combination antifungal therapy in the treatment of IA in different
patient populations. Deﬁnitions of invasive fungal disease from the
European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group of 200234 were used to review
articles published before the 2008 revision. For the article
published in 2010,35 the revised deﬁnitions of 2008 were
applied.36 We included only those patients diagnosed with either
proven or probable IA.
2.2. Eligibility criteria
We included cohort and RCT studies that assessed the efﬁcacy
of combination antifungal therapy and reported on clinical
outcomes, without restriction to language. Two reviewers (MAG
and FAA) independently assessed the eligibility and quality of
studies addressing the role of combination antifungal therapy in
the treatment of IA.
2.3. Search strategy
A senior experienced librarian searched MEDLINE, EMBASE,
Web of Science, Cochrane Central Register of Controlled Trials, and
Scopus from inception up to March 2011 for any relevantcomparative studies (RCT and cohort studies) published in any
language. The search was conducted using these key words:
invasive SAME (aspergillosis OR aspergillus) AND (dual OR
combination OR combined) AND (‘‘anti-fungal’’ OR antifungal)
AND Topic= (random OR blind OR trial OR cohort OR ‘‘case series’’
OR retrospective OR prospective OR evidence OR ‘‘meta-analysis’’).
We sought additional studies by reviewing the reference lists of
eligible studies and relevant review articles. The complete search
strategy is available on request from the authors. The search was
extended to include all trials (completed and on-going) on
combination antifungal therapy for IA from www.clinicaltrials.gov.
2.4. Screening and data extraction
Following completion of the search, all titles and abstracts were
screened for possible inclusion in the review. Screening was based
on the study being an RCT or a cohort study that was conducted on
humans, and addressing our topic of interest. Studies were excluded
only if the screener could be sure that it did not fulﬁll our inclusion
criteria. Screening of titles and abstracts was conducted in duplicate
by the two reviewers independently. Disagreement was resolved by
subsequent discussion. A third author (IMT) resolved disagreements
that could not be solved by consensus.
2.5. Quality assessment
The Newcastle–Ottawa quality assessment scale37 for cohort
studies is intended to assess for selection bias, comparability of the
exposed and unexposed groups of each cohort, outcome assess-
ment, and attrition bias. Two reviewers independently evaluated
these components of the scale. There was 100% agreement (k = 1).
We assessed the quality of the RCT using the method of Ju¨ni et al.38
3. Results
3.1. Search results
The initial search yielded 363 abstracts for screening, 328 of
which were excluded: 114 were considered non-relevant, 149
were review articles or commentaries, 31 were animal or basic
research, 30 studies had non-clinical outcomes, and 4 were
guidelines. Thirty-ﬁve abstracts were considered for full review
(Figure 1). Eight studies9,13,20,23,35,39–41 (one RCT and seven
cohorts) were eligible for ﬁnal review (Table 1) with a total of
1071 patients with either proven or probable IA diagnosed
according to the initial34 and revised36 deﬁnitions from the
EORTC/MSG Consensus Group. The modiﬁed Newcastle–Ottawa
quality assessment scale37 was used to assess the methodological
quality and the possibility of bias among the cohort studies. Table 2
shows that the included cohort studies were of good methodolog-
ical quality and shared most of the characteristics examined.
The search was extended to include all trials (completed,
terminated, withdrawn, and on-going) on combination antifungal
therapy for IA from www.clinicaltrials.gov (Table 3). This yielded
nine trials, three of which have been completed; two out of these
were non-comparative trials while the third (COMBISTRAT) was a
randomized pilot study and has been included in our review.40 On
the other hand, two of the trials were terminated due to
inadequate enrollment and one trial was withdrawn prior to
enrollment. Moreover, three intervention trials comparing combi-
nation and monotherapy in patients with IA are currently ongoing
(Table 3). The ﬁrst compares the efﬁcacy of a combination of
micafungin and voriconazole versus voriconazole/placebo
(NCT01207128) and the second anidulafungin and voriconazole
versus voriconazole monotherapy (NCT00531479); both are
prospective, randomized, double-blind international trials that
363 Studies retrieved from initial database search 
328 Studies excluded after abstract review: 
• 114 Not relevant 
• 149 Reviews/commentaries 
• 31 Basic and animal research 
• 30 Non-clinical outcomes 
• 4 Guidelines 
35 Considered for full text review 
27 Studies excluded: 
• 8 Case series 
• 19 Non-comparative studies 
8 Eligible studies included for the review: 
• 1 RCT 
• 7 Cohort studies 
Figure 1. Flow chart of the study selection process.
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randomized, open-label, single-center trial comparing the efﬁcacy
of anidulafungin and voriconazole versus voriconazole mono-
therapy in patients with IA aged 2 to 17 years (NCT01188759), is
yet to start recruiting.
3.2. Characteristics of the included studies
A summary of the studies included in our systematic review is
presented in Table 1. The sample sizes of the reviewed studies
varied widely (21–405). The reviewed studies varied also in the
antifungal drugs used in combination. Seven of the studies had a
follow-up duration of 12 weeks, while the study duration was not
mentioned in the eighth.41 We compared the outcomes of the
different antifungal regimens in different patient populations
included in the review. Studies that used similar drugs were
compared. Two groups of three studies compared voriconazole/
caspofungin combinations9,20,23 and amphotericin B/caspofun-
gin,35,39,40 respectively, while the remaining two studies compared
the combinations of amphotericin B/itraconazole.13,41
The three studies9,20,23 that used the combination of vorico-
nazole and caspofungin compared it with either voriconazole or
lipid formulation of amphotericin B as monotherapy. This
combination was used in patients with hematologic malignancies
and in solid organ transplant recipients. One study observed that
the use of caspofungin and voriconazole combination therapy was
associated with a signiﬁcant reduction in mortality compared with
monotherapy,20 while another showed only a trend.23 However,
the study by Upton et al.,9 did not show any signiﬁcant difference
between the combination and monotherapy groups. The most
frequently observed adverse events in the combination group
included transaminitis (22.5%), visual disturbances (15%), hallu-
cinations (5%), and cutaneous rash (5%). These, however, did not
lead to discontinuation of therapy.23
Among those treated with amphotericin B (as deoxycholate or
lipid formulation) either alone or in combination with itracona-
zole,13,41 no signiﬁcant difference was observed in their response
rates, even though no adjusted analyses were provided. Mildincreases in total bilirubin and transaminases were noticed in the
combination groups, while none in the monotherapy group.41
In a cohort of patients with hematologic malignancy and IA,39
multiple regression analysis showed that the combination of a
high-dose lipid formulation of amphotericin B (HD-LPD/AMB) and
caspofungin was associated with a signiﬁcantly lower likelihood of
a favorable response than posaconazole salvage therapy (odds
ratio 0.25, 95% conﬁdence interval 0.07–0.91; p = 0.03). The study
also showed that posaconazole was better tolerated than the
combination, with signiﬁcantly lower rates of renal and hepatic
toxicity (p  0.02).
In the study by Mihu et al.,35 a favorable response was achieved
in 21% of patients treated with a combination of a lipid formulation
of amphotericin B (L-AMB) and echinocandins at the end of
12 weeks of salvage therapy vs. 28% of patients treated with
echinocandins and 9% of those treated with L-AMB (p = 0.04,
unadjusted analysis). Overall toxicity in the combination group
was 31% vs. 6% in the echinocandin group and 26% in the L-AMB
group (p = 0.03).
In the RCT,40 30 patients (21 men and nine women) with
hematologic malignancies were prospectively randomized in an
open trial (COMBISTRAT) to receive either a combination of a
standard dose of liposomal amphotericin B (3 mg/kg/day) and
caspofungin, or monotherapy with a high-dose amphotericin B
(10 mg/kg/day). At the end of treatment, there were signiﬁcantly
more favorable overall responses (partial or complete responses;
p = 0.028) in the combination group (10 of 15 patients; 67%)
compared with the high-dose monotherapy group (four of 15
patients; 27%). Survival rates at 12 weeks after inclusion were 100%
and 80%, respectively, among those on combination and mono-
therapy.
4. Discussion
Our systematic review identiﬁed eight comparative studies
(one RCT and seven cohorts) published in any language up to
March 2011 that assessed the efﬁcacy of combination antifungal
therapy for the treatment of IA among various hosts.
Six studies9,13,23,39–41 examined the role of combination therapy
for primary IA and two for salvage therapy.20,35 Of the seven
cohort studies, four reported adjusted effect estimates,9,20,23,39
one of which showed a better outcome with combination
antifungal therapy20 and one a trend towards a better outcome,23
while the remaining two revealed that there was no added
advantage of combination antifungal therapy over monotherapy9
or a better response with monotherapy.39 In one pilot RCT,40
combination therapy was associated with a better outcome.
Different antifungal combinations were used where caspofungin
was added to either voriconazole or amphotericin B products.
Given the heterogeneity of the treatment regimens, patient
populations, endpoints, and conﬂicting results, the cumulative
evidence is not strong enough to support routine combination
therapy for primary IA. Our ﬁndings are consistent with the recent
IDSA guidelines, which stated that there are limited clinical data
to support combination antifungal therapy over single-agent
therapy for the primary treatment of IA.
An international multicenter, randomized, double-blind, con-
trolled trial (NCT00531479) comparing the safety and efﬁcacy of
anidulafungin plus voriconazole versus voriconazole monotherapy
for the treatment of IA is currently recruiting. Another single-center,
randomized, double-blind, placebo-controlled trial (NCT01207128)
of voriconazole and micafungin versus voriconazole monotherapy
(plus placebo) in IA is also recruiting. A single-center study of the
efﬁcacy of voriconazole and anidulafungin combination versus
voriconazole monotherapy for IA in pediatric subjects aged 2 to
17 years is yet to start recruiting patients at the time of writing this
Table 1
Characteristics of included studies
Reference Study
population
Sample
size
Female,
n (%)
Age range
or mean
(years)
Study
design
Indication for
combination
therapy
Treatment category Follow-up
duration
(weeks)
Outcome of
combination vs.
monotherapy
Adjusted effect estimates
Combination Monotherapy
Popp et al.,
199941
Hematologic
malignancy
21 8 (38) 44.95 Cohort Primary AMB 1 mg/kg/day+ itraconazole
400 mg/day caps or suspension
AMB 1 mg/kg/day NR Favorable
response
No adjusted analysis;
univariate analysis:
82% vs. 50%, p=0.12
Marr et al.,
200420
Hematologic
malignancy
47 29 (61.7) 16–66 Cohort Salvage Voriconazole 6 mg/kg q12h IV
for 1 day, then 4 mg/kg q12h 
caspofungin 70mg IV for 1 day,
then 50 mg/day
AMB 1 mg/kg/day and
LFABs 5 mg/kg/day
for those with pre-existing
renal disease or intolerance
to AMB
12 Mortality HR 0.28, 95% CI 0.1–0.92
Kontoyiannis
et al., 200513
Hematologic
malignancy
179 112 (62.6) 30–66 Cohort Primary LipoAMB 5 mg/kg/day+
itraconazole 200mg IV/PO bid,
then 200mg qd
LipoAMB 5 mg/kg/day 12 Favorable
response
No adjusted analysis;
univariate analysis:
0% vs. 10%, p=not
signiﬁcant
Singh et al.,
200623
Organ
transplant
recipients
87 36 (41.4) 19–68 Cohort Primary Voriconazole 6 mg/kg q12h IV
for 1 day, then 4 mg/kg q12h+
caspofungin 70mg IV on day 1,
then 50 mg/day
LipoAMB 5.2 mg/kg/day 12 Mortality HR 0.58, 95% CI 0.3–1.14,
p=0.11
Upton et al.,
20079
Bone marrow
transplant
recipients
405 165 (40.7) 42.2 Cohort Primary Voriconazole  caspofungin Voriconazole (before 1996:
AMB 0.5 mg/kg/day;
after 1996: LipoAMB
5 mg/kg/day)
12 Mortality HR 2.3, 95% CI 0.6–9.4,
p=0.23
Raad et al.,
200839
Hematologic
malignancy
143 24 (16.8) 43.7 Cohort Primary HD-LPD/AMB 7.5 mg/kg/day 
caspofungin 70mg on day 1 and
50–100 mg/day
Posaconazole (salvage)
400mg PO q12h as
outpatient or 200mg by
NG tube q6h or 800mg q24h
12 Favorable
response
OR 0.25, 95% CI 0.07–0.91,
p=0.03
Caillot et al.,
200740
Hematologic
malignancy
30 9 (30) 16–75 RCT Primary LipoAMB 3 mg/kg/day IV+
caspofungin 70mg IV for 1 day,
then 50 mg/day
LipoAMB 10 mg/kg/day 12 Favorable
response
4/15 (27%) vs. 10/15 (67%),
p=0.028
Mihu et al.,
201035
Hematologic
malignancy
141 54 (38.3) 9–79 Cohort Salvage L-AMB+echinocandin
(90% caspofungin) (no dosage)
L-AMB (no dosage) or
echinocandin
(89% caspofungin)
(no dosage)
12 Mortality No adjusted estimates;
62% combination vs. 61%
echinocandins vs. 67% L-AMB,
p=0.78
39 (44) 9–80 Favorable
response
No adjusted estimates;
21% combination vs. 28%
echinocandins vs. 9% L-AMB,
p=0.04
AMB, conventional amphotericin B; bid, twice daily; 95% CI, 95% conﬁdence interval; HD-LPD/AMB, high-dose lipid formulation of amphotericin B; HR, hazard ratio; IV, intravenous; L-AMB, lipid formulation of amphotericin B;
LFABs, amphotericin B lipid complex or liposomal amphotericin B; LipoAMB, liposomal amphotericin B; NR, not reported; OR, odds ratio; NG tube, nasogastric tube; PO, per os (oral); q6h, every 6h; q12h, every 12h; q24h, every
24h; qd, four times daily; RCT, randomized controlled trial.
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Table 3
List of studies on combination antifungal therapy and their status from www.clinicaltrials.gov
Identiﬁer Status Study Condition Intervention (drugs)
Monotherapy Combination
NCT00334412 Completed COMBISTRAT: AmBisome1 in
combination with caspofungin
for the treatment of invasive
aspergillosis
Invasive aspergillosis AmBisome1 AmBisome1+ caspofungin
NCT00047827 Terminated Trial of micafungin (FK463) in
combination with liposomal
amphotericin B (AmBisome1)
for aspergillosis
Aspergillosis Non-comparative Micafungin + LPD-amphotericin B
NCT00076869 Completed MK0991 in combination with
standard antifungal agent(s)
for the treatment of salvage
invasive aspergillosis
Aspergillosis Non-comparative MK0991; caspofungin,
amphotericin B or liposomal
amphotericin B and/or azole
NCT00531479 Recruiting Anidulafungin plus voriconazole
versus voriconazole for the
treatment of invasive aspergillosis
Aspergillosis Voriconazole Voriconazole + anidulafungin
NCT00620074 Terminated;
has results
Study to test the combination
of voriconazole and anidulafungin
in patients who have, or are
thought to have, invasive
aspergillosis and who are unable
to take a common antifungal
therapy (polyene)
Aspergillosis Voriconazole Voriconazole + anidulafungin
NCT00423163 Withdrawn A study to evaluate the
effectiveness of voriconazole +
micafungin versus voriconazole
alone for invasive aspergillosis
Aspergillosis/blood
aspergillosis/invasive
Voriconazole Voriconazole + micafungin
NCT00037206 Completed A safety and effectiveness study
of intravenous anidulafungin with
AmBisome1 for treatment of IA
Aspergillosis Non-comparative Anidulafungin + AmBisome1
NCT01207128 Recruiting Trial of combination antifungal
therapy (Vori + Mica vs. Vori +
Placebo) in invasive aspergillosis
Invasive aspergillosis Voriconazole + placebo Voriconazole + micafungin
NCT01188759 Not yet
recruiting
Voriconazole and anidulafungin
combination for invasive
aspergillosis in pediatric subjects
Invasive aspergillosis Voriconazole Voriconazole + anidulafungin
LPD-amphotericin B, lipid formulation of amphotericin B; IA, invasive aspergillosis; Vori, voriconazole; Mica, micafungin.
Table 2
Modiﬁed Newcastle–Ottawa quality assessment scale for cohort studies included in the review
Reference Selectiona Comparabilityb Outcomec
Representativeness
of the exposed
cohort
Selection of the
non-exposed
cohort
Ascertainment
of exposure
Incident
disease
Assessment
of outcome
Length of
follow-up
Adequacy of
follow-up
Popp et al.,199941 A A A A A B NR NR
Marr et al., 200420 A A A A A B A A
Kontoyiannis et al.,
200513
A A A A A B A A
Singh et al., 200623 A A A A A B A A
Upton et al., 20079 A A A A A B A A
Raad et al., 200839 A A A A A B A A
Mihu et al., 201035 A A A A A B A A
NR, not reported.
a Selection: (1) Representativeness of the exposed cohort: A, truly representative of the average patient; B, somewhat representative of the average patient; C, selected group;
D, no description of the derivation of the cohort. (2) Selection of the non-exposed cohort: A, drawn from the same community as the exposed cohort; B, drawn from a different
source; C, no description of the derivation of the non-exposed cohort. (3) Ascertainment of exposure: A, secure record (e.g., surgical record); B, structured interview; C, written
self-report; D, no description. (4) Incident disease, for demonstration that the outcome of interest was not present at start of study: A, yes; B, no.
b Comparability: For comparability of cohorts on the basis of the design or analysis: A, study controls for co-morbidities; B, study controls for any additional factor (e.g., age
and severity of illness); C, not done.
c Outcome: (1) Assessment of outcome: A, independent blind assessment; B, record linkage; C, self-report; D, no description. (2) Length of follow-up, was follow-up long
enough for outcomes to occur?: A, yes; B, no. (3) Adequacy of follow-up: A, complete follow-up and all subjects accounted for; B, subjects lost to follow-up but unlikely to
introduce bias because a small number were lost (i.e., >90% were available for follow-up) or a description was provided of those lost; C, follow-up rate 90% or lower and no
description of those lost; D, no statement.
M.A. Garbati et al. / International Journal of Infectious Diseases 16 (2012) e76–e81e80manuscript. Once these studies are completed, it is hoped that the
role of combination antifungal therapy will become clearer.
In conclusion, cumulative evidence supporting the use of
combination antifungal therapy in IA is conﬂicting and of moderatestrength. Well-designed controlled, randomized, multicenter
clinical trials are required to adequately address the issue of the
usefulness of this approach. Data from ongoing RCTs to address this
controversy are patiently awaited.
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